Sandoz opens €150m manufacturing facility
pharmafile | September 18, 2015 | News story | Manufacturing and Production | Austria, BioInject, Novartis, Sandoz
Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria.
Known as BioInject will result in the creation of 100 jobs. Sandoz is looking to consolidate its position as a global leader in biosimilar medicines, having recently launched Zarxio, the first biosimilar to reach the US market.
BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics. The new facility now means that 18,000 syringes can be filled and 100 packaged per minute.
The plant will play an important role in driving the next wave of biosimilars and novel biologics growth at Sandoz and Novartis Pharmaceuticals – growth that will ultimately help address unmet medical needs and broaden patient access to key biologics products.
At the opening ceremony Carol Lynch, global head of biopharmaceuticals and oncology injectables at Sandoz, said: “BioInject stands as a testament to both Sandoz’ technological leadership in biologics as well as the company’s commitment to further strengthening its global leadership in biosimilars.” BioInject will become a central part of Novartis’ biomanufacturing network which also includes facilities in Slovenia, Singapore and France.
The investment means Novartis – which owns Sandoz – has invested more than €2.2 billion in the Austrian pharma industry since Novartis was first established in 1996. The group currently has over 4,600 employees at four sites and is therefore an important economic contributor, particularly in the provinces of Tyrol, Upper Austria and Vienna.
Lilian Anekwe
Related Content
Sandoz launches two new bone disease biosimilars in Europe
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 …
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
